Sagimet Biosciences logo
Sagimet Biosciences
SGMT | NASDAQ
Chart Builder DCF Calculator
$10.13
-$0.09 (-0.88%)
At close: Nov 16, 2026, 4:00 PM ET
$10.33
+$0.20 (+1.97%)
After-hours: Nov 16, 2026, 7:30 PM ET

Sagimet Biosciences Company Profile

Company profile explained

Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Key Executives

Name Position
David A. Happel Chief Executive Officer, President & Director
Thierry Chauche Chief Financial Officer & Principal Accounting Officer
Andreas Grauer Chief Medical Officer
Elizabeth Rozek Chief Legal & Administrative Officer
Lucas Pelkmans Co-Founder
Marie O'Farrell Chief Scientific Officer
Robert D'Urso Senior Vice President of New Products
Urs Greber Co-Founder

Latest SEC Filings

Date Type Title
Oct 22, 2026 8-K Current Report
Oct 07, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 01, 2026 8-K Current Report
Oct 01, 2026 424B5 Filing
Sep 30, 2026 8-K Current Report
Sep 30, 2026 424B3 Filing
Aug 17, 2026 4 Filing
Aug 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 13, 2026 8-K Current Report
Aug 12, 2026 4 Filing
View All SEC Filings ➞
Sagimet Biosciences
Sagimet Biosciences logo
Country United States
IPO Date Jul 14, 2023
Industry Biotechnology
Sector Healthcare
Employees 16
CEO David Happel

Contact Details

155 Bovet Road San Mateo, California 94402 United States

Stock Details

Ticker Symbol SGMT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001400118
CUSIP Number 786700104
ISIN Number US7867001049
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.